AKBA Q3 2018 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+28.8% YoY

Gross Profit

-$17M-32.8% margin

Operating Income

-$28M-52.4% margin

Net Income

-$26M-49.0% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$404M

Total Liabilities

$261M

Stockholders' Equity

$143M

Cash & Equivalents

$162M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$41M	+28.8%
Gross Profit	-$17M	-$17M	-0.2%
Operating Income	-$28M	-$24M	-15.2%
Net Income	-$26M	-$23M	-12.6%

Revenue Segments

License And Service

$53M100%